OSE Immunotherapeutics

143 articles with OSE Immunotherapeutics

• OSE Immunotherapeutics Presents OSE-230 as a Novel Agonist Monoclonal Antibody Therapy Triggering Resolution of Chronic Inflammation

  10/30/2020

  The first presentation of new data characterizing the anti-ChemR23 antibody was at the FOCIS Virtual Annual Meeting held October 28-31, 2020

• OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation

  10/22/2020

  NANTES, France, Oct. 22, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced a publication in the prestigious Journal of Clinical Investigation (JCI) of translational and preclinical study data in rodent in vivo and human ex vivo models characterizing the efficacy and mechanism of action of BI 765063, formerly OSE-172, the first selective antibody antagonist of SIRPα-mediated “Don’t Eat Me” signals. Importantly, for the first time ever the

• OSE Immunotherapeutics Receives European Patent Notice of Allowance for First-in-Class CD28-Antagonist Immunotherapy FR104

  10/12/2020

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the European Patent Office’s (EPO) issuance of a notice of allowance for its Phase-2 ready product FR104, a first-in-class selective CD28-antagonist. Specifically, this European patent will provide additional protection covering novel dosing regimen of FR104 for the prevention and treatment of T-lymphocyte-mediated autoimmune diseases, inflammatory diseases, transplantation and

• 

  BioSpace Global Roundup, Sept. 24

  9/24/2020

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020

  9/21/2020

  Data include significant increase to overall survival and good safety profile in non-small cell lung cancer patients after failure with checkpoint inhibitor therapies

• OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update

  9/17/2020

  Positive results for Step-1 of Phase 3 clinical trial of Tedopi ® in non-small cell lung cancer Positive preclinical and in human ex vivo results with CoVepiT vaccine against COVID-19; clinical entry expected by the end of 2020 or early 2021 Two Phase 2 clinical trials with OSE-127 planned to start in Q4 2020 in ulcerative colitis and in the Sjögren syndrome Strong progress on BiCKI ® , bi-specific platform, and CLEC-1 antagonist preclinical programs in immuno-oncology €7 million

• OSE Immunotherapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference September 14 - 16, 2020 (Virtual Conference)

  9/8/2020

  OSE Immunotherapeutics announced it will present at the H.C. Wainwright 22nd Annual Global Investment Conference.

• OSE Immunotherapeutics Publishes Positive Preclinical COVID-19 Vaccine Results With Multi-Target Vaccine CoVepiT

  8/17/2020

  Data support potential as novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2targets with technology known to induce memory T lymphocytes

• 

  Biopharma Update on the Novel Coronavirus: August 17

  8/17/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.

• OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program

  7/16/2020

  OSE Immunotherapeutics announced it will receive a grant of up to €200,000 from Nantes Metropole, the metropolitan area of Nantes community, dedicated to the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.

• OSE Immunotherapeutics Announces Results of 2020 Virtual Combined General Meeting

  6/16/2020

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

• OSE Immunotherapeutics Presents New Data Supporting Bispecific Antibody Checkpoint Inhibitor Platform (BiCKI®) and Bifunctional Therapy Targeting PD-1 and IL-7 (BiCKI®-IL-7) For Cancer Immunotherapy

  6/10/2020

  Data being presented in two poster presentations at AACR Virtual Meeting II 2020 – June 22-24

• OSE Immunotherapeutics Announces Procedures for Virtual Combined General MeetingLive Webcast Login Information

  5/27/2020

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the procedures for participating in the Combined General Meeting, to be held on June 16, 2020 at 2:30 p.m. CET.

• OSE Immunotherapeutics Signs €7 Million Non-Dilutive Loan Agreement Guaranteed by the French State

  5/26/2020

  OSE Immunotherapeutics, announced the signature of a €7 million non-dilutive loan agreement, with a pool of French banks, providing the company with further financing to advance its clinical and preclinical development programs.

• OSE Immunotherapeutics Presents CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer ImmunotherapyOral Presentation at AACR Virtual Meeting II 2020 – June 22-24

  5/18/2020

  Tumor cells inhibit myeloid cell phagocytosis and dendritic cell antigen presentation through the novel “Don’t eat me” signal mediated by CLEC-1

• OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program

  5/5/2020

  OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company is committed to the fight against COVID-19. Its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.

• 

  Clinical Catch-Up: March 30 – April 3

  4/6/2020

  This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
• 

  OSE Lung Cancer Trial Hits the Mark, But COVID-19 Could Delay Ongoing Clinical Plans

  4/2/2020

  A late-stage lung cancer drug under development by OSE Immunotherapeutics met its 12-month primary endpoint for survival rates following a Step-1 analysis.
• 

  Biopharma Update on the Novel Coronavirus: April 2

  4/2/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.

• Phase 3 Clinical Trial of Tedopi®: OSE Immunotherapeutics Announces Positive Top-Line Results for Step-1 of its trial ‘Atalante 1’ in Non-Small Cell Lung Cancer

  4/1/2020

  Step-1 primary endpoint met: 12-month survival rate in Tedopi® treated patients;